Terms: = Brain cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
69 results:
1. The diagnostic and prognostic potential of the egfr/MUC4/MMP9 axis in glioma patients.
Quesnel A; Coles N; Polvikoski TM; Karagiannis GS; Angione C; Islam M; Khundakar AA; Filippou PS
Sci Rep; 2022 Nov; 12(1):19868. PubMed ID: 36400876
[TBL] [Abstract] [Full Text] [Related]
2. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy.
Gempt J; Withake F; Aftahy AK; Meyer HS; Barz M; Delbridge C; Liesche-Starnecker F; Prokop G; Pfarr N; Schlegel J; Meyer B; Zimmer C; Menze BH; Wiestler B
ESMO Open; 2022 Oct; 7(5):100566. PubMed ID: 36055049
[TBL] [Abstract] [Full Text] [Related]
3. The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare egfr extracellular domain M277E mutation and high PD-L1 expression.
Lv D; Wang R; Wang X; Feng H
J Cancer Res Ther; 2022 Apr; 18(2):587-589. PubMed ID: 35645132
[TBL] [Abstract] [Full Text] [Related]
4. Can a signature molecular-profile define disparate survival in BRAF-positive Gliosarcoma and identify novel targets for therapeutic intervention?
Gandhi P; Khare R; Garg N; Mishra J
J Cancer Res Ther; 2022; 18(1):224-230. PubMed ID: 35381788
[TBL] [Abstract] [Full Text] [Related]
5. clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of egfr mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
Zeng Y; Guo T; Zhou Y; Zhao Y; Chu L; Chu X; Yang X; Ni J; Zhu Z
BMC Cancer; 2022 Feb; 22(1):198. PubMed ID: 35189835
[TBL] [Abstract] [Full Text] [Related]
6. Rational application of gefitinib in NSCLC patients with sensitive egfr mutations based on pharmacokinetics and metabolomics.
Feng W; Chen X; Guan SX; Ruan HL; Huang Y; Zhang HZ; Yang YP; Fang WF; Zhao HY; Zhuang W; Xin S; Chen YH; Wang F; Gao Y; Huang M; Wang XD; Zhang L
Acta Pharmacol Sin; 2022 Jul; 43(7):1857-1864. PubMed ID: 34737420
[TBL] [Abstract] [Full Text] [Related]
7. Dysregulated miR-137 and its target egfr contribute to the progression of pituitary adenomas.
Wei D; Yu Z; Cheng Y; Jiawei H; Jian G; Hua G; Guilan D
Mol Cell Endocrinol; 2021 Jan; 520():111083. PubMed ID: 33246030
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
[TBL] [Abstract] [Full Text] [Related]
9. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
[TBL] [Abstract] [Full Text] [Related]
10. clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between egfr TKI-naïve and TKI-resistant.
Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
[TBL] [Abstract] [Full Text] [Related]
12. Effects of different brain surveillance strategies on outcomes for patients with egfr-mutant metastatic lung adenocarcinoma under targeted therapy.
Shen CI; Huang HC; Chiang CL; Luo YH; Shiao TH; Chiu CH
Lung Cancer; 2019 Dec; 138():52-57. PubMed ID: 31634655
[TBL] [Abstract] [Full Text] [Related]
13. clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R
Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704
[TBL] [Abstract] [Full Text] [Related]
14. SEL1L plays a major role in human malignant gliomas.
Mellai M; Annovazzi L; Boldorini R; Bertero L; Cassoni P; De Blasio P; Biunno I; Schiffer D
J Pathol Clin Res; 2020 Jan; 6(1):17-29. PubMed ID: 31111685
[TBL] [Abstract] [Full Text] [Related]
15. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.
Manneh Kopp RA; Sepúlveda-Sánchez JM; Ruano Y; Toldos O; Pérez Núñez A; Cantero D; Hilario A; Ramos A; de Velasco G; Sánchez-Gómez P; Hernández-Laín A
Clin Transl Oncol; 2019 Oct; 21(10):1413-1423. PubMed ID: 30877636
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic significance of genetic biomarkers in isocitrate dehydrogenase-wild-type lower-grade glioma: the need to further stratify this tumor entity - a meta-analysis.
Vuong HG; Tran TTK; Ngo HTT; Pham TQ; Nakazawa T; Fung KM; Hassell L; Katoh R; Kondo T
Eur J Neurol; 2019 Mar; 26(3):379-387. PubMed ID: 30298540
[TBL] [Abstract] [Full Text] [Related]
17. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer.
Machado-Rugolo J; Fabro AT; Ascheri D; Farhat C; Ab'Saber AM; de Sá VK; Nagai MA; Takagaki T; Terra R; Parra ER; Capelozzi VL
Hum Pathol; 2019 Jan; 83():177-191. PubMed ID: 30218756
[TBL] [Abstract] [Full Text] [Related]
18. Common Co-activation of AXL and CDCP1 in egfr-mutation-positive Non-smallcell Lung cancer Associated With Poor Prognosis.
Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
[TBL] [Abstract] [Full Text] [Related]
19. High expression of Bruton's tyrosine kinase (BTK) is required for egfr-induced NF-κB activation and predicts poor prognosis in human glioma.
Yue C; Niu M; Shan QQ; Zhou T; Tu Y; Xie P; Hua L; Yu R; Liu X
J Exp Clin Cancer Res; 2017 Sep; 36(1):132. PubMed ID: 28946903
[TBL] [Abstract] [Full Text] [Related]
20. Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol - Insights From Japanese Chronic Heart Failure (J-CHF) Study.
Nagatomo Y; Yoshikawa T; Okamoto H; Kitabatake A; Hori M;
Circ J; 2018 Feb; 82(3):691-698. PubMed ID: 28883225
[TBL] [Abstract] [Full Text] [Related]
[Next]
